The Royal Marsden Hospital Foundation Trust
Welcome,         Profile    Billing    Logout  
 16 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bono, Johann De
PROfound, NCT02987543 / 2016-000300-28: Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer ( Study)

Checkmark Quality of life data from PROfound trial in mCRPC
Feb 2022 - Feb 2022: Quality of life data from PROfound trial in mCRPC
Checkmark Acceptance of regulatory submission in China for prostate cancer (based on PROfound trial)
Jun 2021 - Jun 2021: Acceptance of regulatory submission in China for prostate cancer (based on PROfound trial)
Checkmark Approved for BRCAm mCRPC with distant metastasis based on PROfound trial
More
Completed
3
387
Europe, Canada, Japan, US, RoW
olaparib, Lynparza, enzalutamide, XTANDI, abiraterone acetate, ZYTIGA
AstraZeneca, Merck Sharp & Dohme LLC, Foundation Medicine, Inc., Myriad Genetics, Inc.
Metastatic Castration-resistant Prostate Cancer
06/19
02/23
PERSEUS1, NCT03506997 / 2017-000931-15: Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

Recruiting
2
100
Europe
Pembrolizumab, Keytruda; MK-3475
Institute of Cancer Research, United Kingdom, Merck Sharp & Dohme LLC
Castration-resistant Prostate Cancer
09/23
09/25
LORIKEET, NCT05848011: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
2
154
Europe, US, RoW
lorigerlimab, MGD019, docetaxel, Taxotere®, Prednisone
MacroGenics
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
09/26
09/27
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Active, not recruiting
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
02/25
NCT03177187 / 2016-003141-28: Combination Study of AZD5069 and Enzalutamide.

Terminated
1/2
30
Europe
AZD5069, Enzalutamide 40 MG, Xtandi
Institute of Cancer Research, United Kingdom, Astellas Pharma Inc, AstraZeneca, Prostate Cancer UK
Metastatic Castration Resistant Prostate Cancer
09/22
11/22
ACTIon, NCT04458311: Abiraterone Acetate in Combination With Tildrakizumab

Terminated
1/2
13
Europe
Abiraterone Acetate, Yonsa, Tildrakizumab
Institute of Cancer Research, United Kingdom, Sun Pharmaceutical Industries Limited
Metastatic Castration Resistant Prostate Cancer
04/23
11/23
NCT06126731: Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Recruiting
1/2
39
Europe
Enzalutamide 40mg, Xtandi, Amoxicillin 500mg, Metronidazole 400mg, Vancomycin 125mg, Ciprofloxacin 500g
Institute of Cancer Research, United Kingdom, Prostate Cancer Foundation
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
06/24
07/25
NCT03568656 / 2018-000285-10: Study to Evaluate CCS1477 in Advanced Tumours

Recruiting
1/2
350
Europe, US
CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
CellCentric Ltd.
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
12/24
12/24
EVICTION, NCT04243499 / 2019-003847-31: First-in-Human Study of ICT01 in Patients With Advanced Cancer

Checkmark Data from EVICTION study in combination with Keytruda for solid tumor at ESMO 2022
Sep 2022 - Sep 2022: Data from EVICTION study in combination with Keytruda for solid tumor at ESMO 2022
Recruiting
1/2
150
Europe, US
IV ICT01
ImCheck Therapeutics, ImCheck Therapeutics, Inc.
Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer
06/25
12/25
CURATE, NCT05272709: TT-702 in Patients With Advanced Solid Tumours.

Recruiting
1/2
188
Europe
TT-702, Darolutamide
Cancer Research UK, Teon Therapeutics, Inc.
Advanced Solid Tumors
06/27
06/27
CRUKD/22/002, NCT05057013: A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Recruiting
1/2
81
Europe
HMBD-001, HMBD-001 and enzalutamide
Cancer Research UK, Hummingbird Bioscience
Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer, RAS Wild Type Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma (HCC), Melanoma, Non-small Cell Lung Cancer (NSCLC), Oesophageal Cancer, Ovarian Cancer, Pancreatic Cancer, Squamous Cell Cancer of the Head and Neck
09/26
09/26
ONCT-534-101, NCT05917470: A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

Terminated
1/2
21
Europe, US
ONCT-534, GTx-534, UT-34
Oncternal Therapeutics, Inc
Metastatic Castration-resistant Prostate Cancer
09/24
09/24
NCT00516373: A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Checkmark The first set of clinical trials based on inhibiting PARP using olaparib
Nov 2015 - Nov 2015: The first set of clinical trials based on inhibiting PARP using olaparib
Completed
1
98
Europe
KU-0059436 (AZD2281)(PARP inhibitor), Olaparib
AstraZeneca
Ovarian Neoplasms, BRCA1 Protein, BRCA2 Protein
12/08
04/23
NCT00516724: Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Checkmark ESMO-ECCO-ESTRO 2013
Sep 2013 - Sep 2013: ESMO-ECCO-ESTRO 2013
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
1
189
Europe
KU-0059436 (AZD2281)(PARP inhibitor), Olaparib, Carboplatin, CBDCA, Paraplatin®, Paclitaxel, Paclitaxel + Carboplatin
AstraZeneca
Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin, Paclitaxel
01/13
04/24
DDRiver Solid Tumours 301, NCT04170153: Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Active, not recruiting
1
161
Europe, Japan, US, RoW
M1774, Tuvusertib, Niraparib
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Metastatic or Locally Advanced Unresectable Solid Tumors
01/26
01/26
POTENTIA, NCT04839991: Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

Recruiting
1
70
Europe, US
CB307
Crescendo Biologics Ltd.
Advanced and/or Metastatic Solid Tumours
07/24
09/24
NCT06458712: Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants with Advanced Malignancies

Recruiting
1
90
Europe
DSB2455
Duke Street Bio Ltd
Advanced Malignancies with Homologous Recombination Deficiency (HRD) (Breast, Ovarian, MCRPC, Brain Metastases)
08/27
08/28
NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Recruiting
1
141
Europe, Canada, Japan, US, RoW
GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
GlaxoSmithKline
Neoplasms
09/28
09/28
MAESTRO, NCT03934164: Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) -

Recruiting
N/A
600
Europe
Institute of Cancer Research, United Kingdom, Prostate Cancer UK
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
03/24
03/25

Download Options